Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3‐year randomized parallel‐controlled study
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Objective: To investigate the effects of long‐term effective control of serum uric acid on renal function in patients with type 2 diabetes and asymptomatic hyperuricemia. Methods: Application of randomized open parallel‐controlled methods, a total of 176 patients with type 2 diabetes and asymptomatic hyperuricemia were selected, and was randomly divided into two groups for allopurinol or conventional treatments, respectively. Changes in urinary albumin excretion rate (UAER), the levels of serum creatinine and glomerular filtration rate (GFR) and the incidence of new‐onset diabetic nephropathy (DN) and hypertension in patients before and after 3 years of treatment were measured and compared between groups. Results: There were no statistically significant difference in the baseline clinical characteristics of study participants between two treatment groups ( P > 0·05 for all). After 3 years of treatment, compared to the conventional treatment, the allopurinol treatment was more effective in reducing serum uric acid, UAER, serum creatinine ( P < 0·01 for all) and increasing GFR ( P < 0·01). The intention‐to‐treat (ITT) analysis indicated that the incidence of new‐onset DN and hypertension in the allopurinol group showed a declining trend compared to that in the conventional treatment group, despite a lack of significant difference ( P > 0·05). Conclusion: Long‐term effective control of serum uric acid can decrease UAER and serum creatinine, increase GFR and may exert kidney protection effects in patients with type 2 diabetes and asymptomatic hyperuricemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Diabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
Zoppini, G., Targher, G., Chonchol, M., Ortalda, V., Abaterusso, C., Pichiri, I., Negri, C., & Bonora, E. (2012) · Diabetes Care · doi:10.2337/dc11-1346 · Cited by 274
Cited by
Johnson, R. J., Bakris, G. L., Borghi, C., Chonchol, M. B., Feldman, D., Lanaspa, M. A., Merriman, T. R., Moe, O. W., Mount, D. B., Sanchez Lozada, L. G., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.009 · Cited by 644
Inflammation in Renal Diseases: New and Old Players
Andrade-Oliveira, V., Foresto-Neto, O., Watanabe, I. K. M., Zatz, R., & Câmara, N. O. S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01192 · Cited by 330
Physiology of Hyperuricemia and Urate-Lowering Treatments
Benn, C. L., Dua, P., Gurrell, R., Loudon, P., Pike, A., Storer, R. I., & Vangjeli, C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00160 · Cited by 319
Pichler, R., Afkarian, M., Dieter, B. P., & Tuttle, K. R. (2017) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00314.2016 · Cited by 295
New progress in drugs treatment of diabetic kidney disease
Wang, J., Xiang, H., Lu, Y., Wu, T., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111918 · Cited by 74
Factors modulating the inflammatory response in acute gouty arthritis
Cleophas, M. C., Crişan, T. O., & Joosten, L. A. B. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000366 · Cited by 62
Diabetic nephropathy: Time to withhold development and progression - A review
Sharaf El Din, U. A. A., Salem, M. M., & Abdulazim, D. O. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.04.004 · Cited by 53
“Treatment of hyperuricemia Three years treatment of T2DM patients suffering DN with allopurinol significantly decreased UAE and serum creatinine and significantly increased GFR [70].”
BackgroundChen, Y., Liu, P., Chen, X., Li, Y., Zhang, F., & Wang, Y. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.01.017 · Cited by 35
Self-citationLiu, P., Liu, R., Chen, X., Chen, Y., Wang, D., Zhang, F., & Wang, Y. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1094044 · Cited by 36
Self-citation
Metadata
- Authors
- Liu, P., Chen, Y., Wang, B., Zhang, F., Wang, D., & Wang, Y.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2014-12-29
- Volume
- 83
- Issue
- 4
- Pages
- 475-482
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2105606034
- Cited by
- 126
- References
- 4
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.